Upregulation of Nuclear Factor-kappaB Expression by SLURP-1 is Mediated by Alpha7-nicotinic Acetylcholine Receptor and Involves Both Ionic Events and Activation of Protein Kinases
Overview
Physiology
Affiliations
SLURP-1 (secreted mammalian Ly-6/urokinase plasminogen activator receptor-related protein-1) is a novel auto/paracrine cholinergic peptide that can bind to α(7)-nicotinic acetylcholine receptor (nAChR), a high Ca(2+)-permeable ion channel coupled to regulation of nuclear factor-κB (NF-κB) expression. Elucidation of intracellular signaling events elicited by SLURP-1 is crucial for understanding the molecular mechanism of functioning of this novel hormone-like peptide that alters vital cell functions and can protect from tumorigenic transformation. In this study, we sought to dissect out the role of α(7)-nAChR in mediating the biologic effects of recombinant SLURP-1 on the immortalized line of human oral keratinocytes Het-1A. A multifold upregulation of the NF-κB expression at the mRNA and protein levels by SLURP-1 was only slightly diminished due to elimination of Na(+), whereas in Ca(2+)-free medium the effect of SLURP-1 was inhibited by >50%. Both in the absence of extracellular Ca(2+) and in the presence of Cd(2+) or Zn(2+), the SLURP-1-dependent elevation of NF-κB was almost completely blocked by inhibiting MEK1 activity. Downstream of α(7)-nAChR, the SLURP-1 signaling coupled to upregulation of NF-κB also involved Jak2 as well as Ca(2+)/calmodulin-dependent kinase II (CaMKII) and protein kinase C (PKC), whose inhibition significantly (P < 0.05) reduced the SLURP-1-induced upregulation of NF-κB. The obtained results indicated that activation of α(7)-nAChR by SLURP-1 leads to upregulation of the NF-κB gene expression due to activation of the Raf-1/MEK1/ERK1/2 cascade that proceeds via two complementary signaling pathways. One is mediated by the Ca(2+)-entry dependent CaMKII/PKC activation and another one by Ca(2+)-independent involvement of Jak2. Thus, there exists a previously not appreciated network of noncanonical auto/paracrine ligands of nAChR of the Ly-6 protein family, which merits further investigations.
Shlepova O, Gornostaeva T, Kukushkin I, Azev V, Bychkov M, Shenkarev Z Acta Naturae. 2025; 16(4):86-94.
PMID: 39877008 PMC: 11771840. DOI: 10.32607/actanaturae.27494.
Cell signaling and epigenetic regulation of nicotine-induced carcinogenesis.
Sun Q, Jin C Environ Pollut. 2024; 345:123426.
PMID: 38295934 PMC: 10939829. DOI: 10.1016/j.envpol.2024.123426.
Senevirathne A, Aganja R, Hewawaduge C, Lee J Pharmaceutics. 2023; 15(10).
PMID: 37896222 PMC: 10609686. DOI: 10.3390/pharmaceutics15102462.
Sun Q, Chen D, Raja A, Grunig G, Zelikoff J, Jin C Toxicol Sci. 2022; 189(2):186-202.
PMID: 35929799 PMC: 9801712. DOI: 10.1093/toxsci/kfac080.
Endogenous α7 nAChR Agonist SLURP1 Facilitates K1 Crossing the Blood-Brain Barrier.
He X, Wang L, Liu L, Gao J, Long B, Chi F Front Immunol. 2021; 12:745854.
PMID: 34721415 PMC: 8552013. DOI: 10.3389/fimmu.2021.745854.